TKI治疗老年晚期非小细胞肺癌的临床研究  

The study of efficacy and toxic between gefitinib and gemcitabine in the treatment of elder-patients with advanced nonsmall cell lung cancer

作　　者：于进彩[1] 王大志[1] 郭成业[1] 安志洁[1] 

机构地区：[1]青岛市市立医院,266071

出　　处：《中国老年保健医学》2015年第1期66-68,共3页Chinese Journal of Geriatric Care

摘　　要：目的进行吉非替尼治疗老年晚期非小细胞肺癌的疗效和毒性反应的临床研究。方法 102例晚期非小细胞肺癌,其中52例给予吉非替尼150mg口服,每日1次,每28天重复。50例予单药吉西他滨1000mg/m2,d1,d8,d15,每28天重复。结果吉非替尼组CR、PR、SD、有效率、疾病控制率、1年生存率分别为3.85%,21.15%,38.46%,38.46%,25.00%,64.50%和28.85%。吉西他滨组CR、PR、SD、有效率、疾病控制率、1年生存率分别为0,24%,32%,24%,56%和26%。两者之间无统计学差异。吉非替尼治疗常见的毒副作用为皮疹和腹泻,总的皮疹发生率为46.15%,腹泻发生率为26.9%,未见间质性肺病和常见的血液学毒性出现。而吉西他滨组的不良反应主要为骨髓抑制和消化道反应。在血液学毒性方面吉西他滨明显高于吉非替尼组,具有统计学差异(P<0.05)。结论吉非替尼和吉西他滨单药治疗老年非小细胞肺癌疗效确切并相当。吉非替尼不仅延长了患者的生存,而且不良反应较轻,值得在临床老年非小细胞肺癌中应用。Objectives To observe the efficacy and toxic of between gefitinib and gemcitabine in treatment of elder-patient with advanced non-small cell lung cancer. Methods 102 elderly patients with advanced non-small cell lung cancer 52 of them were trea- ted with gefitinib at the dose of 150rag p. o. per day, every 28 days. 50 of them were treated with gemcitabine 1000mg/m^2 on day 1 , 8,15,every 28 days. Results Gefitinib group CR. PR. SD. PD. response rate. 1-year survival rate was3.85% ,21. 15% ,38.46% , 38.46% , 25.00% , and 28.85% . Gemcitabine group CR. PR. SD. PD. response rate. 1-year survival rate was 0% , 24% , 32% , 24% , and 26%. There was no statistical significance in two groups effeeiency. Main adverse effects of gefifinib were generally mild （ grade I or II） , including shin rash 46. 15% ） , diarrhea（ 26. 90% ）. Main adverse effects of gemcitabine were Bone marrow suppres- sion and Gastrointestinal reactions. The Bone marrow suppression and Gastrointestinal reactions of two groups were statistical signifi- cance （ P 〈 0. 05 ）. Conclusions Gefitinib and gemeitabine are not only effective in the first line treatment of elderly patients with advanced NSCLC. The treatment with gefitinib in advanced stage small cell lung cancer is effective and safe. All the old patients have slight adverse sides and well compliance and tolerability.

关 键 词：吉非替尼 吉西他滨 治疗 老年非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]